Prudentia Sciences

The company's core offering is a technology platform that serves biopharma companies, biotech firms, and financial institutions such as venture capital and private equity. The platform utilizes artificial intelligence, including large language models and deep learning neural networks, combined with scientific expertise and financial modeling to accelerate the evaluation of drug assets. It aims to reduce the due diligence process from weeks to a single week. Key features include rapid synthesis of data room information, real-time data simulation for asset valuation, and scenario planning to optimize deal terms. The system is designed to help users identify risks, make faster go/no-go decisions, and optimize trade-offs across time, cost, probability of success, and revenue. This service is particularly relevant as the biopharma industry faces a "patent cliff," increasing the need for faster asset assessment.

Prudentia Sciences operates on a B2B model, providing its software to business development, investment, and diligence teams. The platform facilitates collaboration between buyers, sellers, and intermediaries with a human-in-the-loop approach that integrates expert insights with AI analytics. The company's public launch was announced in January 2025, supported by an initial $7 million in seed funding led by GV (Google Ventures), with participation from Iaso Ventures and Virtue. Prudentia has since raised a total of $27 million, including a $20 million Series A round led by McKesson Ventures in January 2026. This capital is intended to expand product capabilities, enhance intelligence for diligence, and scale commercial operations into Asia-Pacific and Europe.